The aim of this study is to provide data and the guidelines for the use of IDRT SL in small wounds, acute and chronic (less than 6 months), showing the benefits and the easy to use of this product as a one stage procedure.

Inclusion Criteria:

• Age ≥ 18 years
• Patient with 1 traumatic wound (burns included) or 1 reconstruction wound (oncological wounds included)
• Patients for whom the surgeon has recommended that an INTEGRA® SL matrix be implanted (even if the patient is not taking part in the study) with a Split Thickness Skin Graft in the same operating procedure
• Wound treated with only one layer of a maximum size 10cm*12.5cm

Exclusion Criteria:

• Immunosuppressed patient
• Chronic wound (with no healing since 6 months)
• Addition of any substances (growth factor, stem cells,…) in the IDRT SL during the surgery
• Patient with a corticoid treatment with a daily dose greater than 5 mg
• Patients whose life expectancy is less than 12 months
• Patients whose mental health or health condition (Visual deficiency, Alzheimers…) would compromise completion of the self-evaluation questionnaires
• Patient with an hypersensitivity to bovine collagen, chondroitin
• Patient with clinical signs of infection (fever, pain, colour, swelling,…) and for whom the investigator diagnosed infection

Global population